Get the Stockscreener App
91.34
2.36%
2.11
After Hours:
91.25
-0.09
-0.10%
Zimmer Biomet Holdings Inc stock is traded at $91.34, with a volume of 1.54M.
It is up +2.36% in the last 24 hours and up +3.60% over the past month.
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly two-thirds of total revenue is derived from sales of large joints; another fourth comes from extremities, trauma, sports medicine, and related surgical products. The firm spun out its dental and spine businesses in 2022.
See More
Previous Close:
$89.23
Open:
$89.69
24h Volume:
1.54M
Relative Volume:
0.66
Market Cap:
$17.67B
Revenue:
$8.41B
Net Income/Loss:
$760.80M
P/E Ratio:
23.72
EPS:
3.8513
Net Cash Flow:
$1.05B
1W Performance:
+4.42%
1M Performance:
+3.60%
6M Performance:
-1.63%
1Y Performance:
-4.00%
1-Day Range:
$89.58
$91.94
1-Week Range:
$86.33
$91.94
52-Week Range:
$79.12
$108.29
Zimmer Biomet Holdings Inc Stock (ZBH) Company Profile
Name
Zimmer Biomet Holdings Inc
Sector
Industry
Phone
(574) 267-6131
Address
345 EAST MAIN STREET, WARSAW, IN
Compare ZBH vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ZBH
Zimmer Biomet Holdings Inc
|
91.34 | 17.67B | 8.41B | 760.80M | 1.05B | 3.8513 |
ABT
Abbott Laboratories
|
93.93 | 163.61B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
329.78 | 126.42B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
83.87 | 107.36B | 36.36B | 4.84B | 5.43B | 3.7212 |
BSX
Boston Scientific Corp
|
44.77 | 66.54B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
92.21 | 53.09B | 6.30B | 1.07B | 1.09B | 1.8406 |
Zimmer Biomet Holdings Inc Stock (ZBH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-23-26 | Downgrade | BTIG Research | Buy → Neutral |
| Feb-20-26 | Initiated | William Blair | Mkt Perform |
| Jan-09-26 | Downgrade | Goldman | Neutral → Sell |
| Jan-06-26 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jan-05-26 | Upgrade | Evercore ISI | In-line → Outperform |
| Dec-16-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Nov-06-25 | Downgrade | JP Morgan | Overweight → Neutral |
| Sep-18-25 | Initiated | Rothschild & Co Redburn | Buy |
| Jul-15-25 | Upgrade | Roth Capital | Neutral → Buy |
| Dec-17-24 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-10-24 | Initiated | Wolfe Research | Peer Perform |
| Jul-01-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| May-30-24 | Initiated | Goldman | Neutral |
| May-21-24 | Upgrade | Argus | Hold → Buy |
| Jan-04-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Oct-20-23 | Initiated | ROTH MKM | Neutral |
| Aug-28-23 | Upgrade | BTIG Research | Neutral → Buy |
| May-03-23 | Upgrade | BofA Securities | Underperform → Neutral |
| Apr-11-23 | Upgrade | Evercore ISI | In-line → Outperform |
| Mar-31-23 | Upgrade | Jefferies | Underperform → Hold |
| Mar-29-23 | Initiated | UBS | Sell |
| Mar-10-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jan-09-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Jan-05-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jan-03-23 | Downgrade | Evercore ISI | Outperform → In-line |
| Nov-23-22 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Oct-18-22 | Initiated | Barclays | Underweight |
| Oct-12-22 | Initiated | Jefferies | Underperform |
| May-27-22 | Downgrade | Needham | Buy → Hold |
| Apr-13-22 | Downgrade | Truist | Buy → Hold |
| Apr-01-22 | Downgrade | Citigroup | Buy → Neutral |
| Mar-02-22 | Resumed | BofA Securities | Underperform |
| Mar-02-22 | Downgrade | Loop Capital | Buy → Hold |
| Feb-08-22 | Downgrade | Canaccord Genuity | Buy → Hold |
| Feb-08-22 | Reiterated | Citigroup | Buy |
| Feb-08-22 | Reiterated | Deutsche Bank | Hold |
| Feb-08-22 | Reiterated | JMP Securities | Mkt Outperform |
| Feb-08-22 | Reiterated | JP Morgan | Neutral |
| Feb-08-22 | Reiterated | RBC Capital Mkts | Sector Perform |
| Feb-08-22 | Reiterated | Stifel | Buy |
| Feb-08-22 | Reiterated | Truist | Buy |
| Feb-08-22 | Reiterated | UBS | Neutral |
| Feb-08-22 | Reiterated | Wells Fargo | Underweight |
| Feb-02-22 | Downgrade | UBS | Buy → Neutral |
| Jan-19-22 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| Jan-10-22 | Downgrade | Mizuho | Buy → Neutral |
| Jan-07-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jan-04-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-10-21 | Initiated | RBC Capital Mkts | Sector Perform |
| Dec-09-21 | Downgrade | Needham | Strong Buy → Buy |
| Dec-07-21 | Initiated | Loop Capital | Buy |
| Nov-23-21 | Downgrade | Argus | Buy → Hold |
| Sep-14-21 | Resumed | Raymond James | Mkt Perform |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-09-21 | Upgrade | Northland Capital | Market Perform → Outperform |
| Jan-04-21 | Upgrade | Evercore ISI | In-line → Outperform |
| Dec-18-20 | Reiterated | Needham | Strong Buy |
| Oct-20-20 | Initiated | Northland Capital | Market Perform |
| Sep-11-20 | Initiated | Wolfe Research | Outperform |
| Aug-05-20 | Reiterated | Needham | Strong Buy |
| Apr-28-20 | Downgrade | Guggenheim | Buy → Neutral |
| Apr-09-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Apr-07-20 | Reiterated | Needham | Strong Buy |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Feb-13-20 | Initiated | Goldman | Buy |
| Jan-08-20 | Initiated | SunTrust | Buy |
| Jan-07-20 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jan-07-20 | Upgrade | Piper Sandler | Neutral → Overweight |
| Dec-04-19 | Upgrade | Raymond James | Outperform → Strong Buy |
| Oct-07-19 | Upgrade | BTIG Research | Neutral → Buy |
| Sep-18-19 | Upgrade | Canaccord Genuity | Hold → Buy |
| Aug-12-19 | Upgrade | Argus | Hold → Buy |
| Jul-30-19 | Upgrade | Barclays | Underweight → Equal Weight |
| Jul-29-19 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Jun-11-19 | Upgrade | Bernstein | Underperform → Mkt Perform |
| Apr-24-19 | Upgrade | Needham | Buy → Strong Buy |
View All
Zimmer Biomet Holdings Inc Stock (ZBH) Latest News
Zimmer Biomet stock holds steady on a broader medtech backdrop - ad-hoc-news.de
ISRG to Report Q2 Results Next Week: Should You Buy the Stock Now? - TradingView
Is Zimmer Biomet Stock the Right Pick for Your Portfolio Now? - Yahoo Finance UK
ZBH stock holds steady as orthopedic demand supports long term outlook - ad-hoc-news.de
Explosive Growth in AI for Orthopedic Surgery Market: $0.87 Billion by 2030 at 27.2% CAGR - GlobeNewswire Inc.
Zimmer Biomet Holdings Inc. stock outperforms competitors on strong trading day - MarketWatch
Global Orthopedic Surgical Robots Market Report Published — Profiles Stryker, Zimmer Biomet, DePuy Synthes, and Medtronic - Yahoo Finance
BMO Capital Initiates Coverage on Zimmer Biomet With Market Perform Rating, $95 Price Target - marketscreener.com
Zimmer Biomet focuses on orthopedic growth. Investors watch long-term demand - Ad-hoc-news.de
Zimmer Biomet (ZBH) Coverage Initiated with Market Perform Ratin - GuruFocus
Zimmer Biomet Holdings Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Zimmer Biomet To Acquire Iovera Pain Therapy Business For $140M - InkFreeNews.com
Citi Maintains Zimmer Biomet Holdings(ZBH.US) With Hold Rating, Maintains Target Price $93 - Moomoo
Zimmer Biomet focuses on orthopedic growth as investors weigh long-term demand - AD HOC NEWS
Zimmer Biomet stock holds focus on execution - AD HOC NEWS
Evercore ISI Adjusts Price Target on Zimmer Biomet to $110 From $120 - Moomoo
Zimmer Biomet stock holds steady on thin coverage. Focus stays on execution. - AD HOC NEWS
Zimmer Biomet acquires rights to medical device for $140 million - Inside INdiana Business
Evercore Maintains Zimmer Biomet Holdings(ZBH.US) With Buy Rating, Cuts Target Price to $110 - Moomoo
JP Morgan Downgrades Zimmer Biomet Holdings (ZBH) - MSN
Zimmer Biomet Holdings, Inc. (ZBH) Stock Analysis: Navigating the Potential 12.84% Upside in the Healthcare Sector - DirectorsTalk Interviews
Enterprise value to revenue forward of Zimmer Biomet Holdings, Inc. – NYSE:ZBH - TradingView
Zimmer Biomet (ZBH) Stock Looks Cheap On Earnings But Faces Growth Doubts - Sahm
Zimmer Biomet Holdings Inc (ZBH) Shares Surge 3.9% -- What GF Sc - GuruFocus
ZBH News | ZIMMER BIOMET HOLDINGS INC (NYSE:ZBH) - ChartMill
Zimmer Biomet (ZBH) director awarded 389 Phantom Stock Units in deferred pay plan - Stock Titan
[Form 4] ZIMMER BIOMET HOLDINGS, INC. Insider Trading Activity - Stock Titan
Form 4 Zimmer Biomet Holdings Inc For: 2 July By Investing.com - Investing.com India
Zimmer Biomet (ZBH) director granted 317.369 cash-settled phantom stock units - Stock Titan
Zimmer Biomet (ZBH) director awarded 317.369 phantom stock units in cash-settled plan - Stock Titan
Phantom stock grant increases Zimmer Biomet (NYSE: ZBH) director units - Stock Titan
Zimmer Biomet (NYSE: ZBH) director receives cash-settled phantom stock grant - Stock Titan
Zimmer Biomet (ZBH) director receives new phantom stock unit award - Stock Titan
Medical device maker Zimmer Biomet to hire 500 in 3 years for tech centre in India - marketscreener.com
Enterprise value to EBIT forward of Zimmer Biomet Holdings, Inc. – NYSE:ZBH - TradingView
Zimmer Biomet (ZBH) Is Buying Pacira’s Iovera Device And Expanding Into Spasticity - Yahoo Finance
Zimmer Biomet Holdings | SD: Specialized disclosure report - Moomoo
‘Cool move’ by Zimmer part of med-tech’s tuck-in deals trend - BioWorld News
Pacira to Divest iovera Business to Zimmer Biomet in Up To $140M Deal - TradingView
Pacira BioSciences to divest its iovera° business to Zimmer Biomet - Medical Buyer
Zimmer Biomet to acquire iovera device from Pacira for $140m - Yahoo Finance
BTIG Maintains Zimmer Biomet Holdings(ZBH.US) With Hold Rating - Moomoo
Persona IQ from Zimmer Biometsmart knee implant brings continuous data to US surgeons - AD HOC NEWS
A Look at Zimmer Biomet Holdings Inc (ZBH) After 5.6% Decline -- GF Value $126.11 vs Price $86.09 - GuruFocus
Zimmer Biomet Holdings, Inc.'s Stock Price Plummets to $86.09, Suffers a Sharp 5.64% Drop - Smartkarma
Zimmer Biomet Holdings Inc. stock underperforms Tuesday when compared to competitors - MSN
Zimmer Biomet Holdings, Inc. agreed to acquire iovera ° Business of Pacira BioSciences from Pacira BioSciences, Inc. for $140 million. - marketscreener.com
Why is Zimmer Biomet stock sliding today? By Investing.com - Investing.com Canada
What is behind Zimmer Biomet stock's recent drop in value today - Traders Union
Pacira BioSciences (PCRX) Sells iovera° Business to Zimmer Biome - GuruFocus
Pacira divests iovera device to Zimmer Biomet for up to $140m - Investing.com
Zimmer Biomet Holdings Inc Stock (ZBH) Financials Data
Revenue
Net Income
Cash Flow
EPS
Zimmer Biomet Holdings Inc Stock (ZBH) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Yi Sang | Group President, Asia Pacific |
May 29 '26 |
Sale |
82.64 |
5,000 |
413,216 |
27,251 |
0.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):